Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-20-000063
Filing Date
2020-08-14
Accepted
2020-08-13 18:23:39
Documents
40
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q awh-20200630x10q.htm 10-Q 1178308
2 EX-31.1 awh-20200630xex31_1.htm EX-31.1 15516
3 EX-31.2 awh-20200630xex31_2.htm EX-31.2 16009
4 EX-32.1 awh-20200630xex32_1.htm EX-32.1 12168
  Complete submission text file 0000926617-20-000063.txt   3821978

Data Files

Seq Description Document Type Size
5 EX-101.INS awh-20200630.xml EX-101.INS 674741
6 EX-101.SCH awh-20200630.xsd EX-101.SCH 27060
7 EX-101.CAL awh-20200630_cal.xml EX-101.CAL 31890
8 EX-101.DEF awh-20200630_def.xml EX-101.DEF 106279
9 EX-101.LAB awh-20200630_lab.xml EX-101.LAB 229046
10 EX-101.PRE awh-20200630_pre.xml EX-101.PRE 200864
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 201100618
SIC: 2835 In Vitro & In Vivo Diagnostic Substances